ARL5A

Across TCGA pan-cancer cohorts, ARL5A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARL5A data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ARL5A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARL5A expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

GBM, PDAC, and LUAD are the cancer types where ARL5A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.212	0.649	<.001	26	view →
PDAC	OS	Median	III,IV	0.967	0.286	.004	20	view →
LUAD	DFS	Tertile	All	1.000	0.195	.020	14	view →
HNSC	OS	Median	All	0.421	1.000	.023	6	view →
CCRCC	OS	Tertile	II,III,IV	0.905	0.661	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARL5A–GBM (OS)

Open the GBM breakdown →